The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices
Authors:
Open Access
- 1 April 2022
- journal article
- research article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 54 (4) , 500-508
Abstract
No abstract availableKeywords
Funding Information
- Bayer
- Medizinische Universität Graz
- Roche
- Boehringer Ingelheim
- Gilead Sciences
- AbbVie
- Meso Scale Diagnostics
- Bristol-Myers Squibb
- Boehringer Ingelheim
This publication has 48 references indexed in Scilit:
- Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol‐related acute‐on‐chronic liver failureLiver International, 2014
- Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranololGut, 2012
- The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease: Figure 1Gut, 2012
- Deleterious Effects of Beta-Blockers on Survival in Patients With Cirrhosis and Refractory Ascites†,‡Hepatology, 2010
- Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapyJournal of Hepatology, 2008
- Beta-Blockers to Prevent Gastroesophageal Varices in Patients with CirrhosisNew England Journal of Medicine, 2005
- Prevention of variceal rebleedingThe Lancet, 2003
- Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosisHepatology, 2002
- The Hemodynamic Response to Medical Treatment of Portal Hypertension As A Predictor of Clinical Effectiveness in the Primary Prophylaxis of Variceal Bleeding in CirrhosisHepatology, 2000
- Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosisHepatology, 1999